non-glp-1 medications GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Indications for GLP-1/GIP RA Summary

The blend is well tolerated, with gastrointestinal effects being the most frequent adverse events and no evidence of clinically significant safety concerns or neutralizing antibody responses to cagrilintide during short-term exposure 1-3

Why pair peptides with MUSE cell therapy

To further substantiate these results, we measured the expression of hexokinase 1 (HK1), a rate limiting enzyme of glycolysis

What makes BPC157 so unique is how it works on a cellular level

Reported changes tend to be gradual and cumulative rather than immediate

Following the CHMP's formal opinion, the final decision will be submitted to the European Commission for a legally binding resolution applicable across all EU Member States.